Drugs / ACAZICOLCEPT
ACAZICOLCEPT
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04227938 | May 2020 | acute graft versus host disease | Alpine Immune Sciences, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04835441 | Jun 2021 → Jul 2024 | systemic lupus erythematosus | Alpine Immune Sciences, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03748836 Comparator | Jan → Nov 2019 | — | Alpine Immune Sciences, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACAZICOLCEPT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095304 ↗ |
| Known as | ALPN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03748836 ↗ |
| Known as | Vigd (variant immunoglobulin domain) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095304 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5095304 ↗ |
| Route | Intravenous | “delivered via intravenous or subcutaneous injection” NCT03748836 ↗ |
| Route | Subcutaneous | “delivered via intravenous or subcutaneous injection” NCT03748836 ↗ |